Results From 10-Patient Case Study Lead to Phase III Clinical Trial for Patients with Duchenne Muscular Dystrophy
Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with
Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.
Muscle weakness begins in early childhood, often causing deformity of the arms, legs and spine. Heart and respiratory muscles often begin to fail before children reach early teen years. Although steroid medications – which often are not well tolerated – and other therapies may ease symptoms and delay the most severe effects, no disease-specific treatment exists, and patients rarely survive into their 30s.
But in this case study of 10 boys with Duchenne muscular dystrophy, also called DMD, a single dose of a drug often prescribed for erectile dysfunction or pulmonary hypertension corrected defective blood vessel mechanisms and restored blood flow to exercising muscles.
“The effects were immediate and dramatic, raising the question: If a single dose restores blood flow to muscle while the drug is in the patient’s system, could ongoing tadalafil administration provide sustained benefits, possibly preserve muscle and slow disease progression? If so, this would offer a new therapeutic strategy for DMD, and we have launched a randomized Phase III clinical trial to find out,” said Ronald Victor, MD, director of the Cedars-Sinai Center for Hypertension, associate director of clinical research at the Heart Institute and the Burns and Allen Chair in Cardiology Research. He is the senior author of a highlighted article in the May 7 online edition of Neurology.
Duchenne muscular dystrophy results from a genetic defect that eliminates a protein called dystrophin in the membranes of muscle cells. For more than 25 years, Victor has studied DMD and a less aggressive but debilitating variant called Becker muscular dystrophy. This form of muscular dystrophy, usually diagnosed in early adulthood, is caused by a reduction, but not absence, of dystrophin.
Victor led a research team that in 2000 discovered that the blood flow abnormality in the muscles of children with DMD was caused by a loss of nitric oxide, a signaling chemical that normally tells blood vessels to relax during exercise, increasing blood flow and oxygenation.
In studies of mice bred to represent diseases of dystrophin deficiency, the researchers found that drugs prescribed for other disorders of blood vessel function could restore muscle blood flow and enable the animals to exercise more, with less muscle injury. Tadalafil, known by the brand names Cialis and Adcirca, and sildenafil, called Viagra and Revatio, have long been approved by the Food and Drug Administration to treat erectile dysfunction and pulmonary hypertension, a serious illness that restricts blood flow to the lungs.
Translating these findings to a human clinical trial, Victor and his colleagues published in 2012 a study showing that tadalafil fully restored blood flow in eight of nine patients with Becker muscular dystrophy.
In the new study, investigators found that when boys with Duchenne muscular dystrophy performed handgrip exercises, the major artery of the arm and the blood vessels in muscles of the forearm failed to respond the way they did in healthy boys of similar ages, 8 to 13. But when the boys with DMD were given a single dose of tadalafil, normal vessel function and blood flow were restored. Similar results occurred when sildenafil, a drug with a similar mechanism of action on vessels but a different chemical structure, was used in place of tadalafil.
“Steroids and cardiac-protective blood pressure medication are increasingly prescribed at early ages for patients with Duchenne muscular dystrophy in an effort to delay by a few years the most devastating effects of the disease. But these treatments have no effect on the blood vessel dysfunction that prevents muscles from getting the oxygen they need,” said Victor. “In contrast, in our study, a single dose of tadalafil or sildenafil had an immediate effect. These are well-studied, well-tolerated drugs that are already on the market. If additional study confirms their benefits, repurposing the drugs for muscular dystrophy patients could quickly transform clinical practice.”
The Latest on: Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Duchenne muscular dystrophy
- Buy Rating Affirmed for Edgewise Therapeutics Amid Anticipated Positive Trial Outcomes and Strategic FDA Alignmenton February 25, 2024 at 8:27 pm
such as Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD), sets a favorable investor expectation. The anticipated data from multiple trials, including Phase 1b, Phase 2, and ...
- 'Funny, caring and charming' Durham lad wins award for looking after brother with muscular dystrophyon February 25, 2024 at 10:01 am
William Jackson, 16, received a President's Award from charity Muscular Dystrophy UK in honour of caring for his brother Louis - who is 12 and has Duchenne muscular dystrophy. William, who is a pupil ...
- Strength Training Safely Boosts Muscular Dystrophy Outcomes, but Further Study Neededon February 21, 2024 at 4:00 pm
Their review demonstrated the positive impact that trunk-oriented strength exercises can have when added to usual care, vs usual care alone, for children whose MD diagnosis is Duchenne muscular ...
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Penn State Health Children's Hospitalon February 21, 2024 at 7:01 am
Leading Duchenne Organization Expands Certification of Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy with Addition of Clinic in Eastern Pennsylvania WASHINGTON, Feb ...
- Herpes-Dementia Link; How COVID Affects the Brain; FDA to Decide on Duchenne Drugon February 20, 2024 at 11:54 am
German researchers showed that SARS-CoV-2 did not persist in brain cells and supported the idea that COVID's neurologic complications may be due to inflammatory immune reactions. ( Nature Neuroscience ...
- Novel ASO screening study paves the way for duchenne muscular dystrophy (DMD) therapy advancementson February 20, 2024 at 2:11 am
This article talks about the identification of a novel ASO (AON-C19) which opens a promising new avenue for Duchenne Muscular Dystrophy (DMD) therapy development.
- Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatmenton February 18, 2024 at 4:00 pm
Santhera Pharmaceuticals has announced the publication of results in the journal Neurology that support the long-term efficacy and safety profile of its Duchenne muscular dystrophy (DMD) drug, Agamree ...
- FDA to review expanded use of Sarepta Duchenne gene therapyon February 16, 2024 at 3:55 am
The Food and Drug Administration will decide by June 21 whether to loosen the restrictions surrounding use of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, the company said ...
- FDA grants fast track status to Edgewise’s Duchenne treatmenton February 14, 2024 at 4:29 am
The designation expedites the development and review of EDG-5506, an oral small molecule for the prevention of contraction-induced muscle damage.
- Duchenne Muscular Dystrophy Market Size Predicted To Hit USD 2.1 Billion By 2031 At 4.7% CAGR, Says AMRon February 13, 2024 at 10:33 pm
Duchenne Muscular Dystrophy Market 2024 Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healt ...
via Bing News